Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer

TITLE:A Phase II non-comparative study of paclitaxel plus carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancer. INDICATION:Second-line

carboplatin
fallopian tube
ovarian epithelial cancer
paclitaxel
recurrent ovarian cancer
  • 10 views
  • 07 Nov, 2020
  • 1 location
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease

death. The current best treatment for Cushing s disease is surgery. If surgery does not work or if the tumor returns, there are no more good treatment options. Vorinostat, which is approved to treat a

pituitary
lymphoma
cushing's syndrome
ACTH
hormones released
  • 21 views
  • 03 Mar, 2021
  • 1 location
Study of Tinostamustine First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

t-cell prolymphocytic leukemia
mycosis
angioimmunoblastic t-cell lymphoma
alemtuzumab
refractory multiple myeloma
  • 0 views
  • 27 Jan, 2021
  • 25 locations
MIBG With Dinutuximab +/- Vorinostat

2 pediatric dose. An expansion cohort of an additional 6 patients will then be enrolled. If tolerable, vorinostat will then be added to the third dose level. A 6 patient expansion cohort may then be

avid
dinutuximab
ganglioneuroblastoma
iobenguane
vorinostat
  • 38 views
  • 29 Jan, 2021
  • 11 locations
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT

transplant conditioning
graft versus host disease
cancer
azacitidine
cell transplantation
  • 2 views
  • 25 Jan, 2021
  • 2 locations
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

The purpose of this research study is to test the safety and tolerability of the combination treatment of the investigational drugs vorinostat and pembrolizumab, in combination with chemotherapy

karnofsky performance status
gliosarcoma
malignant glioma
cancer
temozolomide
  • 67 views
  • 26 Jan, 2021
  • 1 location
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective

drug combinations
isof
growth factor
blood transfusion
g-csf
  • 3 views
  • 24 Jan, 2021
  • 1 location
Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease

This Clinical Trial is an open, non-randomized Phase Ib study to determine the maximal tolerable dose (MTD) of Vorinostat in Alzheimer disease (AD) patients between (including) 55 and 90 years

mini-mental state examination
mental state examination
  • 25 views
  • 23 Jan, 2021
  • 4 locations
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find out if

solid tumour
stage iv non-small cell lung cancer
ROS1
chemoradiotherapy
proto-oncogene tyrosine-protein kinase ros
  • 0 views
  • 26 Jan, 2021
  • 1 location
Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons

receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours. Each

  • 1 views
  • 25 Jan, 2021
  • 1 location